DK3143019T3 - Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril - Google Patents
Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril Download PDFInfo
- Publication number
- DK3143019T3 DK3143019T3 DK15726337.7T DK15726337T DK3143019T3 DK 3143019 T3 DK3143019 T3 DK 3143019T3 DK 15726337 T DK15726337 T DK 15726337T DK 3143019 T3 DK3143019 T3 DK 3143019T3
- Authority
- DK
- Denmark
- Prior art keywords
- thiadiazinan
- dioxido
- carbonitrile
- isoquinoline
- methyl
- Prior art date
Links
- KZVYWCGVTGWQCR-XADCJTSKSA-N 6-[(4R)-4-methyl-2-oxido-1-oxo-1,2,6-thiadiazinan-2-ium-2-yl]isoquinoline-1-carbonitrile Chemical compound C[C@H]1C[N+](S(NC1)=O)([O-])C=1C=C2C=CN=C(C2=CC1)C#N KZVYWCGVTGWQCR-XADCJTSKSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993693P | 2014-05-15 | 2014-05-15 | |
| US201562138037P | 2015-03-25 | 2015-03-25 | |
| PCT/IB2015/053194 WO2015173684A1 (en) | 2014-05-15 | 2015-05-01 | Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3143019T3 true DK3143019T3 (da) | 2021-01-04 |
Family
ID=53276206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15726337.7T DK3143019T3 (da) | 2014-05-15 | 2015-05-01 | Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9920043B2 (enExample) |
| EP (1) | EP3143019B1 (enExample) |
| JP (1) | JP6523782B2 (enExample) |
| KR (1) | KR101817889B1 (enExample) |
| CN (1) | CN106459025B (enExample) |
| AU (1) | AU2015260906B2 (enExample) |
| CA (1) | CA2891398C (enExample) |
| CY (1) | CY1123826T1 (enExample) |
| DK (1) | DK3143019T3 (enExample) |
| ES (1) | ES2845639T3 (enExample) |
| HU (1) | HUE052692T2 (enExample) |
| IL (1) | IL248918A0 (enExample) |
| MX (1) | MX371014B (enExample) |
| PL (1) | PL3143019T3 (enExample) |
| PT (1) | PT3143019T (enExample) |
| RU (1) | RU2698194C2 (enExample) |
| SG (1) | SG11201608320QA (enExample) |
| SI (1) | SI3143019T1 (enExample) |
| TW (1) | TWI553007B (enExample) |
| WO (1) | WO2015173684A1 (enExample) |
| ZA (1) | ZA201606796B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2864079T3 (es) * | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| WO2023275715A1 (en) * | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089139A2 (en) | 1982-03-16 | 1983-09-21 | Beecham Group Plc | Antibiotics, their preparation and use |
| US4489075A (en) * | 1982-05-15 | 1984-12-18 | Pfizer Inc. | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2004110978A2 (en) | 2003-06-10 | 2004-12-23 | Smithkline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
| BRPI0413820A (pt) * | 2003-08-22 | 2006-10-24 | Ligand Pharm Inc | derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio |
| CN101945853B (zh) * | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| MY176727A (en) * | 2012-12-03 | 2020-08-20 | Pfizer | Selective androgen receptor modulators |
-
2015
- 2015-05-01 WO PCT/IB2015/053194 patent/WO2015173684A1/en not_active Ceased
- 2015-05-01 ES ES15726337T patent/ES2845639T3/es active Active
- 2015-05-01 EP EP15726337.7A patent/EP3143019B1/en not_active Not-in-force
- 2015-05-01 PT PT157263377T patent/PT3143019T/pt unknown
- 2015-05-01 DK DK15726337.7T patent/DK3143019T3/da active
- 2015-05-01 SG SG11201608320QA patent/SG11201608320QA/en unknown
- 2015-05-01 PL PL15726337.7T patent/PL3143019T3/pl unknown
- 2015-05-01 MX MX2016014999A patent/MX371014B/es active IP Right Grant
- 2015-05-01 SI SI201531479T patent/SI3143019T1/sl unknown
- 2015-05-01 CN CN201580025357.8A patent/CN106459025B/zh not_active Expired - Fee Related
- 2015-05-01 AU AU2015260906A patent/AU2015260906B2/en not_active Ceased
- 2015-05-01 RU RU2016144671A patent/RU2698194C2/ru active
- 2015-05-01 HU HUE15726337A patent/HUE052692T2/hu unknown
- 2015-05-01 KR KR1020167031696A patent/KR101817889B1/ko not_active Expired - Fee Related
- 2015-05-01 US US15/310,570 patent/US9920043B2/en active Active
- 2015-05-13 JP JP2015097829A patent/JP6523782B2/ja not_active Expired - Fee Related
- 2015-05-14 CA CA2891398A patent/CA2891398C/en active Active
- 2015-05-14 TW TW104115438A patent/TWI553007B/zh not_active IP Right Cessation
-
2016
- 2016-10-03 ZA ZA2016/06796A patent/ZA201606796B/en unknown
- 2016-11-13 IL IL248918A patent/IL248918A0/en unknown
-
2021
- 2021-02-18 CY CY20211100138T patent/CY1123826T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2891398A1 (en) | 2015-11-15 |
| EP3143019B1 (en) | 2020-12-16 |
| PL3143019T3 (pl) | 2021-03-22 |
| HUE052692T2 (hu) | 2021-05-28 |
| AU2015260906B2 (en) | 2017-08-31 |
| EP3143019A1 (en) | 2017-03-22 |
| JP2015218166A (ja) | 2015-12-07 |
| TW201546069A (zh) | 2015-12-16 |
| AU2015260906A1 (en) | 2016-10-20 |
| MX371014B (es) | 2020-01-10 |
| RU2698194C2 (ru) | 2019-08-23 |
| CN106459025B (zh) | 2019-05-28 |
| RU2016144671A (ru) | 2018-06-15 |
| PT3143019T (pt) | 2021-01-28 |
| SG11201608320QA (en) | 2016-11-29 |
| KR20160144478A (ko) | 2016-12-16 |
| US20170073338A1 (en) | 2017-03-16 |
| CY1123826T1 (el) | 2022-05-27 |
| KR101817889B1 (ko) | 2018-01-11 |
| CA2891398C (en) | 2019-09-24 |
| WO2015173684A1 (en) | 2015-11-19 |
| US9920043B2 (en) | 2018-03-20 |
| TWI553007B (zh) | 2016-10-11 |
| CN106459025A (zh) | 2017-02-22 |
| IL248918A0 (en) | 2017-01-31 |
| MX2016014999A (es) | 2017-04-11 |
| JP6523782B2 (ja) | 2019-06-05 |
| RU2016144671A3 (enExample) | 2018-06-15 |
| SI3143019T1 (sl) | 2021-03-31 |
| ZA201606796B (en) | 2018-04-25 |
| ES2845639T3 (es) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286428A (en) | Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases | |
| IL259406B (en) | Heterocyclic compounds as immunomodulators | |
| PT3360864T (pt) | Composto de pirimidina | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| PT3157915T (pt) | Compostos de dihidroisoquinolinona substituídos | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3514109T3 (da) | Hydropyrolyse af biomasseholdige råmaterialer | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| IL246385B (en) | Crystalline forms of efitinib di-malate | |
| IL250022A0 (en) | New converted pyrimidine compounds | |
| EP3227309C0 (en) | CRYSTALLINE DIFUCOSYLLACTOSE | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser | |
| LT3597189T (lt) | Kristaliniai junginia | |
| HUE042043T2 (hu) | Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek | |
| EP3346592A4 (en) | Rotating machine | |
| DK3372589T3 (da) | Pyrimidinderivat | |
| DK3630725T3 (da) | Krystallinsk form af n-butyldeoxygalactonojirimycin | |
| EP3467158A4 (en) | Crucible | |
| EP3497152C0 (en) | Polypropylene composition | |
| DK3380453T3 (da) | Syntese af beta-mercaptoethanol | |
| IL248918A0 (en) | Crystal structure of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile | |
| IL258039A (en) | Crystalline forms |